Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3

被引：0
|
作者：
Park, K. [1 ]
Tan, D. [2 ]
Ahn, M. -J. [3 ]
Yu, C. -J. [4 ]
Tsai, C. -M. [5 ]
Hida, T. [6 ]
Nishio, M. [7 ]
Branle, F. [8 ]
Emeremni, C. [9 ]
Mok, T. [10 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Med Oncol, Singapore, Singapore
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] Natl Taiwan Univ, Dept Internal Med, Taipei 10764, Taiwan
[5] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[6] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[7] Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo, Japan
[8] Novartis Pharma AG, Oncol Clin Dev, Basel, Switzerland
[9] Novartis Pharma AG, Biometr & Data Management, E Hanover, NJ USA
[10] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419O
引用
收藏
页码：126 / 127
页数：2
相关论文
共 50 条
  • [31] Efficacy of ALK Inhibitors in the Treatment of ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases: A Meta-analysis
    Luo, P.
    Fan, J.
    Zou, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2373 - S2373
  • [32] Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
    Scagliotti, G.
    Kim, T. M.
    Crino, L.
    Liu, G.
    Gridelli, C.
    Novello, S.
    Kiura, K.
    Bearz, A.
    Gautschi, O.
    Felip, E.
    Nishio, M.
    Spigel, D. R.
    Mok, T. S. K.
    Urban, P.
    Deudon, S.
    Zheng, C.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK plus non-small cell lung cancer (NSCLC) in the ASCEND-8 trial
    Cho, B. C. Chul
    Kim, D-W.
    Batra, U.
    Park, K.
    Kim, S-W.
    Yang, C. T.
    Jye, V. Pie
    Sriuranpong, V.
    Babu, K. G.
    Amin, K.
    Wang, Y.
    Wang, L.
    Bhering, M.
    Geater, S. Lucien
    ANNALS OF ONCOLOGY, 2020, 31 : S864 - S865
  • [34] Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
    Califano, Raffaele
    Greystoke, Alastair
    Lal, Rohit
    Thompson, Joyce
    Popat, Sanjay
    LUNG CANCER, 2017, 111 : 51 - 58
  • [35] Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Sutradhar, Santosh
    Li, Siyu
    Szczudlo, Tomasz
    Yovine, Alejandro
    Shaw, Alice T.
    LANCET ONCOLOGY, 2016, 17 (04): : 452 - 463
  • [36] Validation of the ALK-Brain Prognostic Index (ALKBPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases
    Tsakonas, G.
    Kamali, C.
    Zerdes, I.
    Koulouris, A.
    Hydbring, P.
    Christopoulos, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S647 - S647
  • [37] Clinical experience in patients with advanced ALK-Rearranged non-small cell lung cancer and brain metastases in China
    Han, Y.
    Ren, K.
    Zhang, H.
    Sun, L.
    Ren, X.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
    Zhang, Isabella
    Zaorsky, Nicholas G.
    Palmer, Joshua D.
    Mehra, Ranee
    Lu, Bo
    LANCET ONCOLOGY, 2015, 16 (13): : E510 - E521
  • [39] Clinical experience with crizotinib in patients (pts) with advanced ALK plus non-small cell lung cancer (NSCLC) and brain metastases
    Crino, L.
    Ahn, M. J.
    Ou, S. H. I.
    Solomon, B. J.
    Costa, D. B.
    Shreeve, S. M.
    Wiltshire, R.
    Selaru, P.
    Zhou, C.
    Riely, G. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S800 - S800
  • [40] Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer
    Rothschild, Sacha I.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 379 - 381
12345